ASCO 2022: NSABP FC-12: A Single-Arm Phase II Study to Evaluate Treatment with Gevokizumab in Patients with Stage II/III Colon Cancer Published Date June 7, 2022 Expand Fullscreen Exit Fullscreen Download PDF Expand Fullscreen